Emerging Business Models in the Pharmaceutical Industries ...

More documents

Recommendations

Info

Overview of the Network Model The new pharma model is based on the network approach and have an in-licensing and out-licensing mechanism, and a network of research companies working on a contract basis. Pharma companies will be more like marketers and venture capitalists, and integrators. Personalised Drugs Biotech New RX Branded RX Generic Natural Products OTC Drugs Source: JSB Intelligence The Network Model Traditional Pharma The Network Framework Integrators will use a robust framework to integrate disparate business units/companies. This approach will take the pharma companies to a focussed portfolio with higher efficiency, reduced R&D lead time, and cost savings. They will save more money in M&A by entering into early alliances or follow the outsourcing model. The Network Model Venture Capitalist Networking In-Licensing Networking Out- Licensing Business Model Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 28
Drivers Leading to Network Model Traditional Big Pharma companies with internal research departments have been posing themselves as research companies, resulting in low research productivity over the last few years. The industry has begun to transform its business model into a networked structure, which in effect is breaking apart the traditional pharma value chain. New model pharma companies are adopting the network research model, which works on the basis of alliances and outsourcing to multiple small and big research organisations and biotech companies. Current Model Future Model Lower Success Rates in R&D Higher Success Ratesin R&D No Modifying diseases Disease Modifying Sequential Integrated Production Product Life Cycle Management Insourcing Outsourcing 10 to 12 years 3 to 4 years Inhouse Integrated R&D Network R&D Low Productivity High Productivity Source: JSB Intelligence The Network Model In the network R&D model, the company will have the liberty to choose the right product at the right price. Early target identification and validation will save considerable time and reduce the risk of last stage failures. Collaborative R&D gives pharma companies a broader product pipeline with stronger and wider therapeutic focus. Companies can leverage technology and benefit from faster time-to-market and cost savings. Presently 20-25% of research is done through contract companies and this figure is expected to increase to 50% in the near future. The sales division is also being outsourced through CSO - Contract Sales Organisations. Some pharma companies are also outsourcing the developing and manufacturing of drugs. Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 29
Page 1 and 2: Emerging Business Models in the Pha
Page 3 and 4: Table of Contents Introduction…
Page 5 and 6: Acronyms Big Pharmas The top global
Page 7 and 8: Introduction Pharma Industry Overvi
Page 9 and 10: Market Segmentation Getting Blurred
Page 11 and 12: Growth in the Pharma Market The pha
Page 13 and 14: Factors Restraining Pharma Market R
Page 16 and 17: Geographic Overview Introduction No
Page 18 and 19: Trends in the Pharma Industry Short
Page 20 and 21: Long Term Strategies - Forward Inte
Page 22 and 23: Long Term Strategies - Targeted Tre
Page 24 and 25: Long Term Strategies - Biotech and
Page 26 and 27: Long Term Strategies - Biotech and
Page 30 and 31: Outsourcing The network approach al
Page 32 and 33: Many of BMS's key drugs are from ot
Page 34 and 35: Growth in Semi Block Busters Even i
Page 36 and 37: Short Term Strategies - Pre- and Po
Page 38 and 39: Short Term Strategies Against Paral
Page 40 and 41: There are two main types of M&Q act
Page 42 and 43: The Revenue Model The market dynami
Page 44 and 45: Short Term and Mid Term Strategies
Page 46 and 47: Top 10 Pharma Companies - Major Mar
Page 48 and 49: Benchmarking - Top 20 Drugs by Sale
Page 50 and 51: Benchmarking by Percentage Growth i
Page 52 and 53: Benchmarking by Geographic Revenue
Page 54 and 55: Rank 1 2 3 4 5 JnJ GSK Company Pfiz
Page 56 and 57: Altace® Biaxin® Zofran® Brands A
Page 58 and 59: Introduction Pfizer is the world's
Page 60 and 61: Introduction GlaxoSmithKline (GSK)
Page 62 and 63: Introduction Merck & Co. develops,
Page 64 and 65: Introduction Aventis’ core busine
Page 66 and 67: Introduction Bristol-Myers Squibb C
Page 68 and 69: Strategic Direction The company aim
Page 70 and 71: Strategic Direction JnJ has been fo
Page 72 and 73: 15% Percentage Revenues by Segment
Page 74 and 75: 12 10 8 6 4 2 0 The Americas Revenu
Page 76 and 77: 20 15 10 5 0 Novartis revenues by S
Page 78 and 79:
Strategic Direction Eli Lilly focus
Page 80 and 81:
New Revenue Models New revenue mode
Page 82:
Contact Us For more information on
show all

Emerging Business Models in the Pharmaceutical Industries ...

Create successful ePaper yourself

Delete template?

Save as template?